« Return to News | Drug Sponsors

Nuvilex restructures for biotechnology focus

Friday, August 23, 2013 12:36 PM

Nuvilex, an international biotechnology company and former provider of natural products, as well as cell and gene therapy solutions for the treatment of diseases, has restructured corporate operations in an effort to focus on its biotechnology core businesses.

The restructuring was precipitated by the company's recent acquisition of Bio Blue Bird, now a wholly owned subsidiary. This acquisition carries with it exclusive worldwide rights to the use of the live-cell encapsulation-based technology for the development of treatments for all types of cancers. This is initially highlighted by the company's preparations for phase III clinical trials of its treatment for advanced, inoperable pancreatic cancer.

The company has restructured and created three new divisions, two of which are biotechnology divisions. The first of these, Nuvilex, will house the live-cell encapsulation technology and all of its associated licenses; the technology will be used for the development of treatments for cancer and diabetes. The second division, Medical Marijuana Sciences, will focus on the use of constituents of Cannabis for the development of treatments for brain and pancreatic cancers. This division will also include certain products from the company's Knock-Out Technologies subsidiary. A third non-biotech division will consist of nutraceutical formulations and their associated product names.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.